Extremely interesting to look back to DNAP's 1st Newsletter to the shareholders:
"We have constructed a library of SNP maps, showing where, in genes, individual human beings differ from one another. Our maps are by far the best in the world. Due mainly to our proprietary (and patent pending) protocols, our SNP maps are deeper and more detailed than those held publicly (NCBI) or privately (such as at Celera, Affymetrix, Incyte, Human Genome Sciences and even Gennaissance). Furthermore, our maps cover the entire length of the gene in the genome. The maps being constructed by others are focused at the ends. This is a crucial point because the depth and breadth of the maps are important! You can think of them as “treasure maps” - the more detailed and accurate the map, the better your chance of finding the treasure. As an investor in DNAPrint genomics, you should feel proud that you own a piece of the most comprehensive and valuable pharmaco-relevant SNP library on the planet.
We continue to write code for the high-throughput and automated mining of complex genetic pattern from our data. When I speak at meetings with executives of other private and publicly held companies, I am continually amazed at how little effort they are putting into genetics IT and discovery. The reason for this is, that it’s hard, and hard things tend to get done last. Thus, any company that builds a system to solve genetics problems on a genomics scale is worth its’ weight in gold. At the close of year one, DNAPrint is about half way to having our informatics platform for solving these problems completed. We have developed 8 different software components of this platform, and filed patents covering their composition and use. For example, we have filed on a proprietary cladistics-based, geometric modeling scheme for identifying epistatic and dominance components of quantitative genetic variance. To our knowledge, there are no other programs like this anywhere in the world.
We have assembled a world-class laboratory with state-of-the-art equipment. We are sequencing well over 1 Million bases per week and scoring about 2,000 genotypes per day.
We have assembled what may well be the most extensive, detailed and valuable pharmacogenomics specimen databank in the world. We have had the foresight to collect multi-drug consent from our donors, and to log everything in their patient files into our database. No other company does this. Since most of our patients are on multiple medications and since we genotype every person at every pharmaco-relevant marker (unlike our competition), we have the ability to perform multiple and simultaneous pharmacogenomics projects. Please appreciate what this means. Using this type of “master” databank, DNAPrint will be able to outrun its competition in getting pharmacogenomics products discovered and developed to market.
Ann
AI
